Literature DB >> 14714889

Remnant epitopes generate autoimmunity: from rheumatoid arthritis and multiple sclerosis to diabetes.

Francis J Descamps1, Philippe E Van den Steen, Inge Nelissen, Jo Van Damme, Ghislain Opdenakker.   

Abstract

Autoimmune diseases are characterized by inflammation and by the development and maintenance of antibodies and T lymphocytes against "self" antigens. Although the etiology of these diseases is unknown, they have a number of cellular and molecular mechanisms in common. Pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor (TNF), are upregulated and activate the inflammatory process. Chemokines recruit and activate leukocytes to release proteases, including matrix metalloproteinases (MMPs). These proteases degrade proteins into remnant fragments, which often constitute immunodominant epitopes. Either by direct loading into major histocompatibility complex (MHC) molecules or after classical antigen uptake, processing and MHC presentation, these remnant epitopes are presented to autoreactive T lymphocytes. Also, posttranslationally modified remnant peptides may stimulate B cells to produce autoantibodies. This forms the basis of the "Remnant Epitopes Generate Autoimmunity" (REGA) model. We have documented evidences for this model in multiple sclerosis (MS), rheumatoid arthritis (RA) and diabetes, which are summarized here. Furthermore, three topics will be addressed to illustrate the importance of glycobiology in the pathogenesis of autoimmune diseases. In MS, gelatinase B or MMP-9 is a pathogenic glycoprotein of which the sugars contribute to its interactions with the tissue inhibitor of metalloproteinases-1 (TIMP-1) and thus assist in the determination of the enzyme activity. In RA, gelatinase B cleaves denatured type II collagen into remnant epitopes, some of which constitute immunodominant glycopeptides. This implies that immunodominant epitope scanning experiments should preferably be done with natural posttranslationally modified glycopeptides, rather than with unmodified (synthetic) peptides. Sugars can also be used as molecular probes to induce autoimmune diseases. One of the best examples is the induction of acute pancreatitis, insulitis and diabetes by streptozotocin. In addition, gelatinase B is upregulated in pancreatitis and cleaves insulin. The most efficient cleavage by gelatinase B leads to a major insulin remnant epitope.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14714889     DOI: 10.1007/978-1-4615-0065-0_5

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  12 in total

1.  Mutation of mouse Mayp/Pstpip2 causes a macrophage autoinflammatory disease.

Authors:  Johannes Grosse; Violeta Chitu; Andreas Marquardt; Petra Hanke; Carolin Schmittwolf; Lutz Zeitlmann; Patricia Schropp; Bettina Barth; Philipp Yu; Rainer Paffenholz; Gabriele Stumm; Michael Nehls; E Richard Stanley
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

2.  Expression of matrix metalloproteinases subsequent to urogenital Chlamydia muridarum infection of mice.

Authors:  K H Ramsey; I M Sigar; J H Schripsema; N Shaba; K P Cohoon
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Inhibition of matrix metalloproteinases protects mice from ascending infection and chronic disease manifestations resulting from urogenital Chlamydia muridarum infection.

Authors:  Muhammad T Imtiaz; Justin H Schripsema; Ira M Sigar; John N Kasimos; Kyle H Ramsey
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

4.  PSTPIP2 deficiency in mice causes osteopenia and increased differentiation of multipotent myeloid precursors into osteoclasts.

Authors:  Violeta Chitu; Viorel Nacu; Julia F Charles; William M Henne; Harvey T McMahon; Sayan Nandi; Halley Ketchum; Renee Harris; Mary C Nakamura; E Richard Stanley
Journal:  Blood       Date:  2012-08-24       Impact factor: 22.113

5.  Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.

Authors:  Michael Hecker; Christiane Hartmann; Ole Kandulski; Brigitte Katrin Paap; Dirk Koczan; Hans-Juergen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2013-05-01       Impact factor: 5.590

6.  Similarities and differences between multiple sclerosis and type 1 diabetes.

Authors:  Valeria Pozzilli; Eleonora Agata Grasso; Valentina Tomassini
Journal:  Diabetes Metab Res Rev       Date:  2021-10-22       Impact factor: 8.128

7.  Identification of Diagnostic Biomarkers, Immune Infiltration Characteristics, and Potential Compounds in Rheumatoid Arthritis.

Authors:  Huihui Chen; Jingyi Zhao; Junhui Hu; Xu Xiao; Wenda Shi; Yinhui Yao; Ying Wang
Journal:  Biomed Res Int       Date:  2022-04-06       Impact factor: 3.411

8.  A community resource benchmarking predictions of peptide binding to MHC-I molecules.

Authors:  Bjoern Peters; Huynh-Hoa Bui; Sune Frankild; Morten Nielson; Claus Lundegaard; Emrah Kostem; Derek Basch; Kasper Lamberth; Mikkel Harndahl; Ward Fleri; Stephen S Wilson; John Sidney; Ole Lund; Soren Buus; Alessandro Sette
Journal:  PLoS Comput Biol       Date:  2006-06-09       Impact factor: 4.475

9.  How Viruses Contribute to the Pathogenesis of Hemophagocytic Lymphohistiocytosis.

Authors:  Ellen Brisse; Carine H Wouters; Graciela Andrei; Patrick Matthys
Journal:  Front Immunol       Date:  2017-09-07       Impact factor: 7.561

10.  Silencing matrix metalloproteinase-13 (Mmp-13) reduces inflammatory bone resorption associated with LPS-induced periodontal disease in vivo.

Authors:  Morgana R Guimaraes-Stabili; Marcell Costa de Medeiros; Danuza Rossi; Angelo Constantino Camilli; Cleslei Fernando Zanelli; Sandro Roberto Valentini; Luis Carlos Spolidorio; Keith Lough Kirkwood; Carlos Rossa
Journal:  Clin Oral Investig       Date:  2020-11-02       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.